Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Oct;92(10):1791-1792.
doi: 10.1002/jmv.25907. Epub 2020 Jun 3.

Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab

Austin R Morrison  1 , Joseph M Johnson  1 , Mayur Ramesh  2 , Patrick Bradley  3 , Jeffery Jennings  3 , Zachary R Smith  1
Affiliations
Comment

Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab

Austin R Morrison et al. J Med Virol. 2020 Oct.
No abstract available

Keywords: coronavirus; disease control; immune responses; immunodulators; interleukin; virus classification.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflict of interests.

Figures

Figure 1
Figure 1
Clinical time course
See this image and copyright information in PMC

Comment in

Comment on

References

    1. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID‐19: a single center experience. J Med Virol. 2020. 10.1002/jmv.25801 - DOI - PMC - PubMed
    1. McCreary EK, Pouge JM. COVID‐19 treatment: a review of early and emerging options. Open Forum Infect Dis. 2020;7(4):ofaa105. - PMC - PubMed
    1. Le RQ, Li L, Yuan W, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell‐induced severe or life‐threatening cytokine release syndrome. Oncologist. 2018;23(8):943‐947. - PMC - PubMed
    1. Giles JT, Sattar N, Gabriel S, et al. Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial. Arthritis Rheumatol. 2020;72(1):31‐40. - PubMed
    1. Flaig T, Douros A, Bronder E, Klimpel A, Kreutz R, Garbe E. Tocilizumab‐induced pancreatitis: case report and review of data from the FDA Adverse Event Reporting System. J Clin Pharm Ther. 2016;41(6):718‐721. - PubMed

Substances